A new prediction model indicates which patients with MGUS should be considered for bone marrow sampling.
When should bone marrow sampling be performed in patients with monoclonal gammopathy of undetermined significance (MGUS)? Currently, algorithmic approaches based on a Mayo Clinic model are used widely (Blood 2005; 106:812), but researchers in Iceland now propose an alternative model based on their iStopMM study.
About 1000 people (median age, 68) with presumed MGUS underwent bone marrow sampling; those with the IgM isotype were excluded. The researchers developed a multivariable model to predict ≥10% plasma cells — indicating a diagnosis of smoldering multiple myeloma — on bone marrow examination. The model incorporated MGUS isotype (i.e., IgG, IgA, light chain, or biclonal), monoclonal protein concentration, free light chain ratio, and tota…
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose